Cleveland BioLabs Inc was incorporated in Delaware in June 2003 as a spin-off company from the Cleveland Clinic Foundation. It is adrug development company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant unmet medical need. Its programs are focused on the implementation of novel pharmacological approaches to control cell death. Its proprietary drug candidates act via unique mechanisms and targets to kill cancer and protect healthy cells. It conducts business in the United States and the Russian Federation and have worldwide development and commercialization rights to all of its product candidates, subject to certain financial obligations to its current licensors. Its lead product candidates are Entolimod, which the Company is developing as a radiation countermeasure and an oncology drug, and Curaxin CBL0137, its lead oncology product candidate. The Company also has an additional clinical stage program and multiple projects in different stages of preclinical drug development. Entolimod, is its most advanced product candidate, a Toll-like receptor 5, or TLR5, agonist, which the Company is developing as a radiation countermeasure for prevention of death from Acute Radiation Syndrome, or ARS, and as an oncology drug. Curaxin CBL0137, is its lead oncology product candidate, that acts through a novel mechanism enabling this compound to simultaneously target three molecular pathways within cancer cells. It competes with both biotechnology and major pharmaceutical companies. Government authorities in the U.S. and in other countries, regulate the research, development, testing, manufacture, packaging, storage, record-keeping, promotion, advertising, distribution, marketing, quality control, labeling and export and import of pharmaceutical products such as those that the Company is developing.